Sino Biopharmaceutical to divest 67% stake in unit CP Qingdao for $253 mln, ET HealthWorld


Bengaluru: Hong Kong-listed Sino Biopharmaceutical will sell a 67 per cent stake in unit CP Pharmaceutical (Qingdao) for 1.82 billion yuan ($253.28 million) to entities controlled by state-owned Guoxin Group, the company said late on Tuesday.

Sino Biopharmaceutical will keep a 26 per cent stake in CP Qingdao after the disposal, the pharmaceutical conglomerate said in a filing to the Hong Kong Stock Exchange.

CP Qingdao, established in China, is mainly involved in research and development, production and sale of osteoporosis medicines and marine pharmaceuticals.

Through the deal, Guoxin Group plans to enter the life and health industry characterised with marine biological pharmaceuticals, Sino Biopharmaceutical said.

The company expects to record a gain of about 1.60 billion yuan on the disposal, subject to audit. ($1 = 7.1858 Chinese yuan)

  • Published On Feb 7, 2024 at 10:49 AM IST

Join the community of 2M+ industry professionals

Subscribe to our newsletter to get latest insights & analysis.

Download ETHealthworld App

  • Get Realtime updates
  • Save your favourite articles

Scan to download App


Leave a Reply

Your email address will not be published. Required fields are marked *